We develop injectable decoy biotherapeutics for the selective and quick removal of harmful circulating antibodies from blood. Our peptide-based decoys can be specifically adapted for vector-neutralizing antibodies in gene therapy, or drug-neutralizing anti-drug antibodies in enzyme- and factor replacement therapies (e.g. glycogen storage diseases, hemophilia & other rare conditions).
Company Details
- Employees
- 8
- Address
- Maria-Jacobi-Gasse 1, Vienna,a- 1030,austria
- Industry
- Biotechnology
- Website
- ablevia.com
- Keywords
- precision medicine, personalized medicine, peptide biotherapeutics, anti-drug antibodies, gene therapy, rare diseases, harmful antibody removal, preclinical development, licensing, biotech, epitope mapping, drug development.
- HQ
- Vienna, A-
Ablevia Biotech Gmbh Questions
Ablevia Biotech Gmbh's website is ablevia.com
Ablevia Biotech Gmbh's LinkedIn profile is https://at.linkedin.com/company/ablevia
Ablevia Biotech Gmbh has
8 employees.
View email and phone details for 8
employees at Ablevia Biotech Gmbh.
Ablevia Biotech Gmbh's industry is
Biotechnology
Ablevia Biotech Gmbh's top competitors are
G.st Antivirals,
Sarcura,
A:head Bio Ag,
Proxygen,
Myllia Biotechnology,
Lexogen,
Quantro Therapeutics Gmbh,
Heartbeat.bio Ag,
Valanx Biotech,
Imd Biotech Gmbh.
Ablevia Biotech Gmbh's categories are Biotechnology
